Immunology

Immunogenicity and In vivo protection of a variant nanoparticle vaccine that confers broad protection against emerging SARS-CoV-2 variants

1. James Logue
2. Robert Johnson
3. Nita Patel
4. Bin Zhou
5. Sonia Maciejewski
6. Haixia Zhou
7. Alyse Portnoff
8. Jing-Hui Tian
9. Marisa McGrath
10. Robert Haupt
11. Stuart Weston
12. Holly Hammond
13. Mimi Guebre-Xabier
14. Carly Dillen
15. Joyce Plested
16. Shane Cloney-Clark
17. Ann M Greene
18. Mike Massare
19. Greg Glenn
20. Gale Smith
21. Matthew Frieman

Reviewed by ScreenIT

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies

1. Alexandra J Spencer
2. Susan Morris
3. Marta Ulaszewska
4. Claire Powers
5. Reshma Kailath
6. Cameron Bissett
7. Adam Truby
8. Nazia Thakur
9. Joseph Newman
10. Elizabeth R Allen
11. Indra Rudiansyah
12. Chang Liu
13. Wanwisa Dejnirattisai
14. Juthathip Mongkolsapaya
15. Hannah Davies
16. Francesca R Donnellan
17. David Pulido
18. Thomas P. Peacock
19. Wendy S. Barclay
20. Helen Bright
21. Kuishu Ren
22. Gavin Screaton
23. Patrick McTamney
24. Dalan Bailey
25. Sarah C Gilbert
26. Teresa Lambe

Reviewed by ScreenIT

Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variant

1. Penny L Moore
2. Thandeka Moyo-Gwete
3. Tandile Hermanus
4. Prudence Kgagudi
5. Frances Ayres
6. Zanele Makhado
7. Jerald Sadoff
8. Mathieu Le Gars
9. Griet van Roey
10. Carol Crowther
11. Nigel Garrett
12. Linda-Gail Bekker
13. Lynn Morris
14. Hanneke Schuitemaker
15. Glenda Gray

Reviewed by ScreenIT

High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells

1. Jennifer S. Chen
2. Ryan D. Chow
3. Eric Song
4. Tianyang Mao
5. Benjamin Israelow
6. Kathy Kamath
7. Joel Bozekowski
8. Winston A. Haynes
9. Renata B. Filler
10. Bridget L. Menasche
11. Jin Wei
12. Mia Madel Alfajaro
13. Wenzhi Song
14. Lei Peng
15. Lauren Carter
16. Jason S. Weinstein
17. Uthaman Gowthaman
18. Sidi Chen
19. Joe Craft
20. John C. Shon
21. Akiko Iwasaki
22. Craig B. Wilen
23. Stephanie C. Eisenbarth

Reviewed by ScreenIT

Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine

1. Jacob Pitcovski
2. Nady Gruzdev
3. Anna Abzach
4. Chen Katz
5. Ran Ben-Adiva
6. Michal Brand-Shwartz
7. Itamar Yadid
8. Einav Ratzon-Ashkenazi
9. Ken Emquies
10. Hadasa Israeli
11. Hadar Haviv
12. Irena Rapoport
13. Itai Bloch
14. Roy Shadmon
15. Zohar Eitan
16. Dalia Eliahu
17. Talia Hilel
18. Morris Laster
19. Sigal Kremer-Tal
20. Tamara Byk-Tennenbaum
21. Ehud Shahar

Reviewed by ScreenIT

Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins

1. José María Díez
2. Carolina Romero
3. María Cruz
4. Peter Vandeberg
5. William Keither Merritt
6. Edwards Pradenas
7. Benjamin Trinité
8. Julià Blanco
9. Bonaventura Clotet
10. Todd Willis
11. Rodrigo Gajardo

Reviewed by ScreenIT

Monitoring Group Activity of Hamsters and Mice as a Novel Tool to Evaluate COVID-19 Progression, Convalescence, and rVSV-ΔG-Spike Vaccination Efficacy

1. Sharon Melamed
2. Boaz Politi
3. Ettie Grauer
4. Hagit Achdout
5. Moshe Aftalion
6. David Gur
7. Hadas Tamir
8. Yfat Yahalom-Ronen
9. Shlomy Maimon
10. Efi Yitzhak
11. Shay Weiss
12. Amir Rosner
13. Noam Erez
14. Shmuel Yitzhaki
15. Shmuel C Shapira
16. Nir Paran
17. Emanuelle Mamroud
18. Yaron Vagima
19. Tomer Israely

Reviewed by ScreenIT

Safety and potency of BIV1‐CovIran inactivated vaccine candidate for SARS‐CoV‐2: A preclinical study

1. Asghar Abdoli
2. Reza Aalizadeh
3. Hossein Aminianfar
4. Zahra Kianmehr
5. Ali Teimoori
6. Ebrahim Azimi
7. Nabbi Emamipour
8. Marzieh Eghtedardoost
9. Vahid Siavashi
10. Hamidreza Jamshidi
11. Mohammadreza Hosseinpour
12. Mohammad Taqavian
13. Hasan Jalili

Reviewed by ScreenIT

Global Analysis of the Mammalian MHC class I Immunopeptidome at the Organism-Wide Scale

1. Peter Kubiniok
2. Ana Marcu
3. Leon Bichmann
4. Leon Kuchenbecker
5. Heiko Schuster
6. David Hamelin
7. Jérome Despault
8. Kevin Kovalchik
9. Laura Wessling
10. Oliver Kohlbacher
11. Stefan Stevanovic
12. Hans-Georg Rammensee
13. Marian C. Neidert
14. Isabelle Sirois
15. Etienne Caron

• Curated by eLife

  Evaluation Summary:

  Kubiniok et al. use published data sets to bioinformatically study the contribution of tissue type and HLA classical class I gene allotype on the immunopeptidome, the repertoire of peptides presented by MHC class I molecules on the cell surface. This is an understudied and critically important question for understanding CD8+T cell tolerance and immunosurveillance of cancer and other diseased cells and autoimmunity, since it enables accurate prediction of peptide targets for vaccines designed to induce or suppress CD8+ T cell responses. Overall, this is a study that draws attention to some of the properties of the antigen processing and presentation pathway that had not been investigated before, namely the known differential gene expression profiles between tissues resulting in the presentation of tissue-specific antigens on HLA-I molecules, which is very valuable. Additionally this study provides avenues for investigation of the involvement of new enzymatic pathways involved in the generation of HLA-I restricted peptides that are presented to CD8+ T cells for immunosurveillance.

Reviewed by eLife

SMRT and NCoR1 fine-tune inflammatory versus tolerogenic balance in dendritic cells by differentially regulating STAT3 signaling

1. Atimukta Jha
2. Abdul Ahad
3. Gyan Prakash Mishra
4. Kaushik Sen
5. Shuchi Smita
6. Aliva Prity Minz
7. Viplov Kumar Biswas
8. Archana Tripathy
9. Shantibhushan Senapati
10. Bhawna Gupta
11. Hans Acha-Orbea
12. Sunil Kumar Raghav

• Curated by eLife

  Evaluation Summary:

  This paper is of interest to immunologists studying the transcriptional control of innate immune responses. The paper presents a new role for transcriptional regulators in the control of inflammatory properties of cross-presenting dendritic cells that are involved in anti-tumoral and anti-viral immunity. The data support the conclusions but some modifications of the text and additional experiments are required.

  (This preprint has been reviewed by eLife. We include the public reviews from the reviewers here; the authors also receive private feedback with suggested changes to the manuscript. The reviewers remained anonymous to the authors.)

Reviewed by eLife